Some clinicians prefer aspirin when balancing bleeding risk with the indication for an anticoagulant, Barnes said, reasoning ...

Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...

as well as advancing other indications in rare cardiovascular conditions requiring chronic anticoagulation; playing a critical role in driving the late-stage clinical development of tecarfarin and ...

Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new Vitamin K ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

as well as advancing other indications in rare cardiovascular conditions requiring chronic anticoagulation; playing a critical role in driving the late-stage clinical development of tecarfarin and the ...

Cadrenal Therapeutics, a biopharmaceutical company listed on the Nasdaq under the ticker symbol CVKD, made a public announcement of leadership changes through an 8-K SEC filing on February 4, 2025.

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

In ascitic patients, paracentesis requires temporary reversion of oral anticoagulation with fresh ... for acute and chronic BCS, and also in patients with fulminant BCS if a liver donor is not ...

webs and a mosaic perfusion pattern should raise suspicion of chronic rather than acute PE. Suggested approach: Patients with a very low or low PESI score may be offered early discharge and outpatient ...

Percentage of biopsies with a diagnosis of cutaneous Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC), or melanoma (including in situ disease) in which the pathologist communicates results ...

For decades, unfractionated heparin (hereafter, heparin) has been the primary anticoagulant used for extracorporeal membrane oxygenation (ECMO) support. More recently, however, bivalirudin, a direct ...